The Mesothelioma Applied Research Foundation (Meso Foundation), the national nonprofit dedicated to eradicating mesothelioma (meso) as a life-ending disease, announced today that illustrious cancer researcher, Nicholas J. Vogelzang, M.D., F.A.C.P., has become the new chair of the Foundation’s Board of Directors. Dr. Vogelzang is the director of Nevada Cancer Institute (NVCI) and formerly served as the director of the University of Chicago’s Cancer Center. He has intense interest in advancing treatments for meso, a diffuse, solid tumor of the lining of the lungs, heart, or abdomen caused by asbestos. He has been involved in a number of the most significant meso clinical trials, and led the clinical trial of Alimta, the first drug ever approved by the FDA specifically for meso. In 2005, he co-edited Malignant Mesothelioma, the leading research clinical textbook on the cancer. Dr. Vogelzang succeeds Roger Worthington, the Meso Foundation’s original chairman and founder. Mr. Worthington conceived the Foundation, formed it in 1999, provided much of the initial funding, and has guided it forward since then. Santa Barbara, CA, August 8, 2006 Press Release/email For more information, contact the Meso Foundation, www.curemeso.org, Executive Director Chris Hahn, 805-563-8400, c-hahn@marf.org. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.